Article

Cutera acquires IRIDEX aesthetic unit

Cutera Inc. and IRIDEX Corp. have entered into a binding agreement for Cutera to purchase certain assets of IRIDEX’s global aesthetic business for about $5.1 million.

Brisbane and Mountain View, CA-Cutera Inc. and IRIDEX Corp. have entered into a binding agreement for Cutera to purchase certain assets of IRIDEX’s global aesthetic business for about $5.1 million.

Currently, both companies serve the growing global aesthetic market, with IRIDEX’s strength in vascular treatments, a mainstay in the dermatology specialty. This proposed strategic combination is expected to advance Cutera’s presence among physicians and create a stronghold in the vascular aesthetic sector.

Kevin Connors, president and chief executive officer of Cutera, said the deal will create one of the most comprehensive portfolios of vascular laser solutions in the industry.

Dominik Beck, PhD, president and chief executive officer of IRIDEX, said the deal allows his company to refocus its resources on “the substantial and growing ophthalmology opportunity that is core to IRIDEX’s future.”

The transaction is expected to close in early 2012.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
(Image credit: Ophthalmology Times) Oluwatosin U. Smith talks Glaukomtecken
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
© 2025 MJH Life Sciences

All rights reserved.